Given the role of legumain in the pathogenesis of Alzheimer’s disease and Parkinson’s disease, it is possible that legumain inhibition contributes to the beneficial effects of statins in these neurodegenerative diseases. This evidence concerns the gene LGMN and early-onset autosomal dominant Alzheimer disease.